negative regulation of low-density lipoprotein particle receptor binding

Definition

Target type: biologicalprocess

Any process that stops, prevents or reduces the frequency, rate or extent of low-density lipoprotein particle receptor binding. [GO_REF:0000059, GOC:BHF, GOC:nc, GOC:TermGenie, PMID:22848640]

Negative regulation of low-density lipoprotein (LDL) particle receptor binding is a complex process that involves a series of molecular interactions and signaling pathways designed to control the uptake of LDL cholesterol from the bloodstream. LDL, also known as "bad cholesterol," is a type of lipoprotein responsible for transporting cholesterol to cells throughout the body. Excess LDL can contribute to the development of atherosclerosis, a condition where plaque builds up in arteries, increasing the risk of heart attacks and strokes. Here's a detailed breakdown of the process:

**1. LDL Receptor (LDLR) Binding:**
* LDLRs are transmembrane proteins found on the surface of cells, primarily liver cells.
* These receptors have a specific binding site for LDL particles, allowing them to bind and initiate the uptake process.

**2. LDL Internalization:**
* Upon binding, LDLR and LDL form a complex that is internalized into the cell via endocytosis. This involves the formation of a vesicle that encapsulates the LDLR-LDL complex.

**3. LDL Transport and Degradation:**
* The vesicle containing LDLR and LDL travels to a compartment within the cell called the lysosome.
* The lysosome contains enzymes that break down LDL, releasing cholesterol into the cell.
* LDLR is recycled back to the cell surface, ready to bind to another LDL particle.

**4. Regulation of LDL Receptor Binding:**
* The process of LDL receptor binding is tightly regulated to maintain optimal cholesterol levels.
* **Negative regulation:** The process of decreasing LDLR binding and subsequent LDL uptake is essential to prevent the accumulation of excess cholesterol.
* **Mechanisms of Negative Regulation:**
* **Statins:** Statins are a class of drugs commonly used to lower cholesterol. They inhibit the synthesis of mevalonate, a precursor to cholesterol, leading to a decrease in LDL production and subsequent receptor binding.
* **SREBPs:** Sterol regulatory element binding proteins (SREBPs) are transcription factors that regulate the expression of genes involved in cholesterol metabolism, including LDLR. When cholesterol levels are high, SREBPs are inhibited, reducing LDLR production and LDL uptake.
* **PCSKs:** Proprotein convertases subtilisin/kexin type 9 (PCSK9) are proteins that bind to LDLR, leading to its degradation. This reduces the number of LDLRs on the cell surface, limiting LDL uptake.
* **Other Factors:** Other factors, such as inflammation, insulin resistance, and genetic predisposition, can also contribute to the negative regulation of LDL receptor binding.

**5. Consequences of Impaired LDL Receptor Binding:**
* Reduced LDL uptake due to negative regulation can lead to the accumulation of LDL in the bloodstream.
* This increased LDL can contribute to the development of atherosclerosis, potentially leading to cardiovascular disease.

In summary, negative regulation of LDL particle receptor binding is a critical process for maintaining cholesterol homeostasis. By controlling the uptake of LDL, the body ensures a delicate balance between cholesterol supply and demand, helping to protect against the development of cardiovascular disease. However, dysregulation of this process can contribute to elevated LDL levels and increased risk for cardiovascular problems.
'
"

Proteins (1)

Compounds (2)